InvesTrust Sells 1,067 Shares of Eli Lilly and Company $LLY

Key Points

• InvesTrust cut its Eli Lilly position by 19.1% in the third quarter, selling 1,067 shares and retaining 4,509 shares valued at approximately $5.2 million. Institutional investors collectively own 82.53% of the company.
• Analysts remain broadly bullish: 24 analysts rate LLY a Buy, with a consensus “Moderate Buy” rating and an average price target of $1,313.43.
• Eli Lilly reported quarterly revenue of $22.97 billion, up 47.7% year over year, and EPS of $8.38, beating estimates. However, the stock’s premium valuation and recent insider selling remain potential risks despite positive pipeline developments.

InvesTrust trimmed its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 19.1% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 4,509 shares of the company's stock after selling 1,067 shares during the quarter. Eli Lilly and Company accounts for about 1.9% of InvesTrust's holdings, making the stock its 19th biggest holding. InvesTrust's holdings in Eli Lilly and Company were worth $5,217,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the period. State Street Corp grew its stake in shares of Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after buying an additional 605,752 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Eli Lilly and Company in the second quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after buying an additional 137,364 shares during the period. Finally, Jennison Associates LLC increased its holdings in shares of Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after buying an additional 400,538 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on LLY shares. Guggenheim boosted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a research note on Friday, September 18th. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a "buy" rating in a research report on Thursday, September 17th. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a research note on Thursday, June 25th. Truist Financial lifted their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,313.43.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh data strengthen Lilly’s immunology franchise. In the LUCENT-2 trial, 27.7% of ulcerative-colitis patients achieved comprehensive disease control after one year, including symptomatic, endoscopic and histologic remission, normalized biomarkers and no corticosteroid use. In the VIVID-1 Crohn’s disease trial, 20.4% achieved corticosteroid-free deep remission. The results also included patients who had previously failed biologic therapies, potentially supporting Omvoh’s commercial positioning. Omvoh clinical data
• Positive Sentiment: Pipeline expansion adds longer-term growth potential. Lilly announced oncology collaborations with Adlai Nortye and Prelude Therapeutics, including evaluation of Adlai’s investigational AN4035 with cetuximab. The partnerships broaden Lilly’s cancer research pipeline and exposure to the growing oncology market. Adlai Nortye collaboration
• Neutral Sentiment: Additional pipeline updates provide background support. Lilly is advancing studies of donanemab in India and lebrikizumab in eczema, while investors remain focused on the potential of retatrutide and other next-generation weight-loss treatments.
• Neutral Sentiment: Upcoming earnings could add volatility. Lilly will report third-quarter 2026 results on October 29. Expectations center on continued strong revenue and earnings growth, particularly from its diabetes and obesity medicines. Lilly earnings announcement
• Negative Sentiment: Valuation remains a risk. After a substantial multiyear rally and trading near its 52-week high, Lilly’s premium valuation leaves the stock dependent on continued exceptional growth and successful pipeline execution. Speculation about a stock split is not a fundamental catalyst.

Eli Lilly and Company Trading Up 3.7%

LLY opened at $1,253.94 on Friday. The stock has a market cap of $1.18 trillion, a PE ratio of 42.08, a PEG ratio of 1.58 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business has a 50 day moving average of $1,178.66 and a 200-day moving average of $1,106.93. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same quarter last year, the company earned $6.31 EPS. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts predict that Eli Lilly and Company will post 34.28 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.